2型糖尿病患者早期使用胰高血糖素样受体激动剂

糖尿病目前已成为继心血管疾病和肿瘤之后的第三位主要非传染性疾病,其中90%为2型糖尿病患者。胰高血糖素样肽-1类似物(GLP-I类似物)作为一种新型的降糖药物,具有降低体重、降低收缩压、改善胰岛细胞功能,已成为2型糖尿病治疗的新热点。艾塞那肽和利拉鲁肽作为肠促胰素激素,与人体内天然GLP-1保持了高度同源性(97%)。近几年来受到人们广泛关注。本综述针对2型糖尿病患者早期使用胰岛素样受体激动剂艾塞那肽和利拉鲁肽的安全性和有效性进行评估。

Early Use of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in Type 2 Diabetes

Diabetes has become,after cardiovascular disease and cancer, the third major non-communicable diseases, of which 90%of type 2 diabetes. Glicagon like peptide-1(GLP-1), was a new antidiabetic drug, which had some effect on decreasing body weight, depressing systolic pressure and improving islet cell function, which has become the treatment of type 2 diabetes new hot spot. Exenatede and liraglutide as incretin hormones, and the body of natural GLP-1to maintain a high degree of homology(97%). In recent year, Glicagon like peptide-1 get much more attention. Here, we review available evidence fromclinical trials regarding the efficacy and safety of GLP-1 RAs.